Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2014 | 9 | 3 | 513-527
Tytuł artykułu

Identifying stakeholder opinion regarding access to “high-cost medicines”: A systematic review of the literature

Treść / Zawartość
Warianty tytułu
Języki publikacji
Objective: To identify the viewpoints and perceptions of different stakeholders regarding high cost medicines (HCMs). Methods: A systematic review of the literature was performed to identify original research articles. Using predefined categories, data related to the viewpoints of different stakeholders was systematically extracted and analyzed. Results: Thirty seven original research articles matched the criteria. The main stakeholders identified include physicians, patients, public and health funding authorities. The influence of media and other economic and ethical issues were also identified in the literature. A large number of stakeholders were concerned about lack of access to HCMs. Physicians have difficulty balancing the the rational use of expensive drugs while at the same time acting as “patients’ advocate”. Patients would like to know about all treatment options, even if they may not be able to afford them. The process and criteria for reimbursement should be transparent and access has to be equitable across patient groups. Conclusion: Access to HCMs could be improved through transparency and involvement of all stakeholders, especially patients and the public. Moral issues and the “rule of rescue” could influence decision-making process significantly. At system level, objectivity is important to ensure that the system is equitable and transparent.

Opis fizyczny
  • University of Auckland, Auckland, New Zealand
  • University of Auckland, Auckland, New Zealand
  • University of Auckland, Auckland, New Zealand
  • [1] Simon F. Market Access For Biopharmaceuticals: New Challenges. Health Aff. 2006; 25(5): 1363–1370[Crossref]
  • [2] Cohen J, Looney W. What is the value of oncology medicines? Nat Biotech. 2010; 28(11): 1160–1163[Crossref]
  • [3] Fojo T, Grady C. How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. Journal of the National Cancer Institute. 2009; 101(15): 1044–1048[Crossref]
  • [4] Puska P. Intervention and experimental studies. Oxford textbook of public health. 1991: 177–187
  • [5] Garattini L, Cornago D, De Compadri P. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy. 2007; 82(3): 330–9.[Crossref]
  • [6] Lu CY, Macneill P, Williams K, Day R. Access to high cost medicines in Australia: ethical perspectives. Aust New Zealand Health Policy. 2008; 5: 4.[Crossref]
  • [7] Mayor S. Time to raise the bar for cancer drug approval? The Lancet Oncology. 2010; 11(1): 16–17[Crossref]
  • [8] Strech D, Synofzik M, Marckmann G. Systematic reviews of empirical bioethics. Journal of Medical Ethics. 2008; 34(6): 472–477[Crossref]
  • [9] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339: b2700[Crossref]
  • [10] Mays N, Pope C. Qualitative research in health care. Assessing quality in qualitative research. BMJ. 2000; 320(7226): 50–52
  • [11] Hedin A. Knowledge-based public health work Part 2. National Institute of Public health. 2004
  • [12] Lu CY, Ritchie J, Williams K, Day R. The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia. Australia & New Zealand Health Policy. 2007; 4: 26[Crossref]
  • [13] Popay J, Arai L, Petticrew M, Roen K. Narrative Synthesis in Systematic Reviews. 2006
  • [14] Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, et al. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol. 2010; 28(27): 4149–4153[Crossref]
  • [15] Berry SR, Hubay S, Soibelman H, Martin DK. The effect of priority setting decisions for new cancer drugs on medical oncologists’ practice in Ontario: a qualitative study. BMC Health Serv Res. 2007; 7:193[Crossref]
  • [16] Blendon RJ, Benson JM, Botta MD, Zeldow D, Kim MK. A four-country survey of public attitudes towards restricting healthcare costs by limiting the use of high-cost medical interventions. BMJ Open. 2012; 2(3)
  • [17] Bullock AJ, Hofstatter EW, Yushak ML, Buss MK. Understanding patients’ attitudes toward communication about the cost of cancer care. Journal of oncology practice / American Society of Clinical Oncology. 2012; 8(4): e50–58[Crossref]
  • [18] Chan KK, Wong B, Siu LL, Straus SE, Chang J, Berry SR. Less than ideal: how oncologists practice with limited drug access. Journal of oncology practice / American Society of Clinical Oncology. 2012; 8(3): 190–195[Crossref]
  • [19] Chao LW PJ, Soldo BJ. End-of-life medical treatment choices: do survival chances and out-of-pocket costs matter? Med Decis Making. 2008; 28(4): 511–523[Crossref]
  • [20] Dare T, Findlay M, Browett P, Amies K, Anderson S. Paternalism in practice: informing patients about expensive unsubsidised drugs. J Med Ethics. 2010; 36(5): 260–264[Crossref]
  • [21] de Kort SJ, Kenny N, van Dijk P, Gevers S, Richel DJ, Willems DL. Cost issues in new diseasemodifying treatments for advanced cancer: Indepth interviews with physicians. European Journal of Cancer. 2007; 43(13): 1983–1989[Crossref]
  • [22] Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ. 2010; 341: c4715[Crossref]
  • [23] Gallego G, Taylor SJ, Brien JA. Setting priorities for high-cost medications in public hospitals in Australia: should the public be involved? Australian health review: a publication of the Australian Hospital Association. 2011; 35(2): 191–196[Crossref]
  • [24] Gallego G, Taylor SJ, Brien J-aE. Priority setting for high cost medications (HCMs) in public hospitals in Australia: A case study. Health Policy. 2007; 84(1): 58–66[Crossref]
  • [25] Gallego G, Taylor SJ, Brien J-aE. Funding and access to high cost medicines in public hospitals in Australia: Decision-makers’ perspectives. Health Policy. 2009; 92(1): 27–34[Crossref]
  • [26] Goldman DP, Jena AB, Lakdawalla DN, Malin JL, Malkin JD, Sun E. The value of specialty oncology drugs. Health Serv Res 2010 Feb;45(1):115–132 Epub 2009 Oct 29. 2009[Crossref]
  • [27] Hind D, Wailoo AJ, Sutcliffe P. Demands for’ offlicence’ access to trastuzumab (Herceptin): content analysis of UK newspaper articles. Health Expect. 2010
  • [28] Huttin C, Andral J. How the reimbursement system may influence physicians’ decisions results from focus groups interviews in France. Health Policy. 2000; 54(2): 67–86[Crossref]
  • [29] Kaser E, Shaw J, Marven M, Swinburne L, Boyle F. Communication about high-cost drugs in oncology-the patient view. Ann Oncol 2010 Sep;21(9):1910–1914 Epub 2010 Mar 23. 2010[Crossref]
  • [30] Kozminski MA, Neumann PJ, Nadler ES, Jankovic A, Ubel PA. How long and how well: oncologists’ attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments. Med Decis Making. 2011; 31(3): 380–385[Crossref]
  • [31] Leighl NB, Tsao WS, Zawisza DL, Nematollahi M, Shepherd FA. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2006; 51(1): 115–121[Crossref]
  • [32] Lu CY, Ritchie J, Williams KM, Day RO. Recent developments in targeting access to high cost medicines in Australia. Aust New Zealand Health Policy. 2005; 2: 28[Crossref]
  • [33] Mackenzie R, Chapman S, Salkeld G, Holding S. Media influence on Herceptin subsidization in Australia: application of the rule of rescue? J R Soc Med. 2008; 101(6): 305–312[Crossref]
  • [34] Martin D, Abelson J, Singer P. Participation in health care priority-setting through the eyes of the participants. J Health Serv Res Policy. 2002; 7(4): 222–229[Crossref]
  • [35] Mehta AB, Low E. Access to expensive drugs in the NHS: myths and realities for cancer patients. Int J Clin Pract. 2007; 61(12): 2126–2129[Crossref]
  • [36] Menon D, Stafinski T, Stuart G. Access to drugs for cancer: Does where you live matter? Can J Public Health. 2005; 96(6): 454–458.
  • [37] Mileshkin L, Schofield PE, Jefford M, Agalianos E, Levine M, Herschtal A, et al. To tell or not to tell: the community wants to know about expensive anticancer drugs as a potential treatment option. Journal of Clinical Oncology. 2009; 27(34): 5830–5837[Crossref]
  • [38] Morgan S, Cunningham CM. Listening for prescriptions: a national consultation on pharmaceutical policy issues. Healthcare policy = Politiques de sante. 2010; 6(2): 48–66
  • [39] Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? The oncologist. 2006; 11(2): 90–95[Crossref]
  • [40] Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer Therapy Costs Influence Treatment: A National Survey Of Oncologists. Health Aff. 2010; 29(1): 196–202[Crossref]
  • [41] Robertson J, Walkom E, Bevan M, Newby D. Medicines and the media: news reports of medicines recommended for government reimbursement in Australia. BMC Public Health. 2013; 13(1): 489[Crossref]
  • [42] Romley JA, Sanchez Y, Penrod JR, Goldman DP. Survey results show that adults are willing to pay higher insurance premiums for generous coverage of specialty drugs. Health Affairs. 2012; 31(4): 683–690[Crossref]
  • [43] Rosenberg-Yunger ZR, Thorsteinsdottir H, Daar AS, Martin DK. Stakeholder involvement in expensive drug recommendation decisions: an international perspective. Health Policy. 2012; 105(2–3): 226–235[Crossref]
  • [44] Schrag D, Hanger M. Medical Oncologists’ Views on Communicating With Patients About Chemotherapy Costs: A Pilot Survey. Journal of Clinical Oncology. 2007; 25(2): 233–237[Crossref]
  • [45] Sinclair S, Hagen NA, Chambers C, Manns B, Simon A, Browman GP. Accounting for reasonableness: Exploring the personal internal framework affecting decisions about cancer drug funding. Health Policy. 2008; 86(2–3): 381–390[Crossref]
  • [46] Singer P. Priority setting for new technologies in medicine: qualitative case study. BMJ. 2000; 321(7272): 1316–1318[Crossref]
  • [47] Thomson J, Schofield P, Mileshkin L, Agalianos E, Savulescu J, Zalcberg J, et al. Do oncologists discuss expensive anti-cancer drugs with their patients? Annals of Oncology. 2006; 17(4): 702–708[Crossref]
  • [48] Ubel PA, Berry SR, Nadler E, Bell CM, Kozminski MA, Palmer JA, et al. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival. Health Affairs. 2012; 31(4): 709–717[Crossref]
  • [49] Wong YN, Hamilton O, Egleston B, Salador K, Murphy C, Meropol NJ. Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices. Oncologist. 2010; 15(6): 566–576[Crossref]
  • [50] Cohen, J., A. Wilson, et al. “Off-label use reimbursement.” Food and drug law journal. 2009 64(2): 391–403
  • [51] Daniels N. Accountability for reasonableness. BMJ. 2000; 321(7272): 1300–1301[Crossref]
  • [52] Zweifel P, Manning WG. Chapter 8 Moral hazard and consumer incentives in health care. In: Anthony JC, Joseph PN, editors. Handbook of Health Economics: Elsevier; 2000. p. 409–459
  • [53] Fenton E. Making Fair Funding Decisions for High-Cost Cancer Care: The Case of Herceptin in New Zealand. Public Health Ethics. 2010 [Crossref]
  • [54] Moynihan R, Heath I, Henry D, Götzsche PC. Selling sickness: the pharmaceutical industry and disease mongering / Commentary: Medicalisation of risk factors. BMJ. 2002; 324(7342): 886–891[Crossref]
  • [55] Boseley S. The selling of a wonder drug. Guardian. 2006; 29
  • [56] Hope T. Rationing and life-saving treatments: should identifiable patients have higher priority? Journal of Medical Ethics. 2001; 27(3): 179–185[Crossref]
  • [57] McKie J, Richardson J. The Rule of Rescue. Social Science & Medicine. 2003; 56(12): 2407–2419[Crossref]
  • [58] Hadorn DC. Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue. JAMA. 1991; 265(17): 2218–25.
  • [59] Weinstein MC. Should physicians be gatekeepers of medical resources? J Med Ethics. 2001; 27(4): 268–274[Crossref]
  • [60] Jenni K, Loewenstein G. Explaining the Identifiable Victim Effect. Journal of Risk and Uncertainty. 1997; 14(3): 235–257[Crossref]
  • [61] Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost effectiveness and resource allocation: C/E. 2006; 4: 14[Crossref]
  • [62] Daniels N, Sabin J. The ethics of accountability in managed care reform. Health Affairs. 1998; 17(5): 50–64[Crossref]
  • [63] Rajender R. A. Research Methods for Pharmaceutical Practice and Policy. 2011
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.